Fibrosis extent on HRCT: the principal structural imaging biomarker for antifibrotic trials
European Respiratory Journal · 29.10.2026 · 2601645
DOI: 10.1183/13993003.01645-2026 ↗Kurz gefasst
Editorial in der Zeitschrift European Respiratory Journal, online erschienen am 29.10.2026. Verfasst von Simon L F Walsh und 3 weiteren Autor:innen. Beteiligte Einrichtung: Qureight Ltd, Cambridge , United Kingdom slfwalsh@gmail.com. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Kein Abstract verfügbar.
Autor:innen und Institutionen
- Qureight Ltd, Cambridge , United Kingdom slfwalsh@gmail.com.
- Imperial College London, National Heart and Lung Institute, London, UK.
- NIHR Imperial Biomedical Research Unit, National Heart and Lung Institute, Imperial College London, London, UK.
- Keck Medicine of USC, University of Southern California, Los Angeles, CA, USA.
- McMaster University, Department of M Respiratory Medicine, Pathology & Molecular Medicine, , Hamilton, ON Canada.
ORCID-Profile: Toby M Maher, Martin Kolb, Philip L Molyneaux
Zitieren
APA
Walsh, S. L. F., Maher, T. M., Kolb, M., & Molyneaux, P. L. (2026). Fibrosis extent on HRCT: the principal structural imaging biomarker for antifibrotic trials. European Respiratory Journal, 2601645. https://doi.org/10.1183/13993003.01645-2026
Vancouver
Walsh SLF, Maher TM, Kolb M, Molyneaux PL. Fibrosis extent on HRCT: the principal structural imaging biomarker for antifibrotic trials. European Respiratory Journal. 2026:2601645. doi:10.1183/13993003.01645-2026
BibTeX
@article{Walsh2026,
author = {Walsh, Simon L F and Maher, Toby M and Kolb, Martin and Molyneaux, Philip L},
title = {Fibrosis extent on HRCT: the principal structural imaging biomarker for antifibrotic trials},
journal = {European Respiratory Journal},
year = {2026},
pages = {2601645},
doi = {10.1183/13993003.01645-2026}
}
EUVIMED